Literature DB >> 8578953

Adenosine deaminase in progressive systemic sclerosis.

P Meunier1, P Filipe, I Emerit, J Freitas, F Guerra Rodrigo, C Manso.   

Abstract

The aim of the present study was to confirm the increase of adenosine deaminase (ADA) activity in progressive systemic sclerosis (PSS), described by Sasaki & Nakajima, and to compare plasma ADA activity of patients in different stages of the disease. Enzyme activity was measured with a colorimetric assay. The 48 patients were subdivided into 3 groups: subgroup 1 (n = 10), disease still limited to the skin; subgroup 2 (n = 21), involvement of the skin and oesophagus; and subgroup 3 (n= 17), involvement of the skin and multiple internal organs. ADA levels were highest in subgroup 3. However, the difference with respect to subgroup 2 did not reach statistical significance. Subgroup 1 was different from controls and subgroups 2 and 3 (p<0.001). Our results confirm that ADA activity is increased in PSS, and that this finding is observed even in the early stages of the disease process. We speculate that the increase in ADA, a well-known marker of T-cell activation, might be an indicator of disease activity in PSS, in the beginning as well as during phases of exacerbation in later stages of the disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8578953     DOI: 10.2340/0001555575297299

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  9 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease.

Authors:  Mustafa Calis; Filiz Ates; Cevat Yazici; Kader Kose; Mehmet Kirnap; Meltem Demir; Murat Borlu; Cem Evereklioglu
Journal:  Rheumatol Int       Date:  2005-05-03       Impact factor: 2.631

3.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

4.  Assessment of adenosine deaminase levels in rheumatoid arthritis patients receiving anti-TNF-alpha therapy.

Authors:  Burak Erer; Gulsen Yilmaz; Fatma Meric Yilmaz; Seyfettin Koklu
Journal:  Rheumatol Int       Date:  2008-10-25       Impact factor: 2.631

5.  Clastogenic factors as potential biomarkers of increased superoxide production.

Authors:  Ingrid Emerit
Journal:  Biomark Insights       Date:  2007-12-11

6.  Pharmacological blockade of A2A receptors prevents dermal fibrosis in a model of elevated tissue adenosine.

Authors:  Patricia Fernández; Sean Trzaska; Tuere Wilder; Luis Chiriboga; Michael R Blackburn; Bruce N Cronstein; Edwin S L Chan
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

7.  Serum Adenosine Deaminase Level is High But Not Related with Disease Activity Parameters in Patients with Rheumatoid Arthritis.

Authors:  Gülseren Demir; Pınar Borman; Figen Ayhan; Tuba Ozgün; Ferda Kaygısız; Gulsen Yilmez
Journal:  Open Rheumatol J       Date:  2014-09-12

8.  A2B adenosine receptor activity is reduced in neutrophils from patients with systemic sclerosis.

Authors:  Laura Bazzichi; Letizia Trincavelli; Alessandra Rossi; Francesca De Feo; Antonio Lucacchini; Stefano Bombardieri; Claudia Martini
Journal:  Arthritis Res Ther       Date:  2004-12-10       Impact factor: 5.156

9.  Serum adenosine deaminase activity in cutaneous anthrax.

Authors:  Mahmut Sunnetcioglu; Sevdegul Karadas; Mehmet Aslan; Mehmet Resat Ceylan; Halit Demir; Mehmet Resit Oncu; Mustafa Kasım Karahocagil; Aysel Sunnetcioglu; Cenk Aypak
Journal:  Med Sci Monit       Date:  2014-07-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.